🔗 Share this article

Treasury head Rachel Reeves has revealed she is preparing "specific measures to tackle cost of living pressures" in the upcoming Budget.

Speaking to media outlets, she noted that curbing inflation is a joint duty of both the government and the central bank.

The UK's price growth is forecast to be the highest among the G7 advanced economies this year and next.

Potential Energy Cost Interventions

Sources suggest the administration could intervene to reduce energy bills, such as by cutting the present 5% level of value-added tax applied on energy.

An additional possibility is to cut some of the policy costs currently included in household expenses.

Budgetary Limitations and Analyst Expectations

The government will receive the next draft from the independent fiscal watchdog, the Office for Budget Responsibility, on Monday, which will reveal how much room there is for these actions.

The expectation from most analysts is that Reeves will have to introduce higher taxes or expenditure reductions in order to meet her declared borrowing rules.

Earlier on the same day, estimates suggested there was a twenty-two billion pound gap for the chancellor to fill, which is at the more modest range of forecasts.

"It is a shared task between the central bank and the government to further reduce some of the causes of inflation," the Chancellor stated to reporters in Washington, at the conferences of the International Monetary Fund and global financial institution.

Revenue Commitments and International Concerns

While a great deal of the focus has been on expected tax increases, the Treasury chief said the latest information from the fiscal watchdog had not altered her pledge to manifesto promises not to raise rates on earnings tax, sales tax or social security contributions.

She attributed an "unpredictable world" with rising geopolitical and trade tensions for the fiscal tax moves, probably to be directed on those "with the broadest shoulders."

International Economic Disputes

Addressing concerns about the UK's commercial links with China she said: "Our national security invariably are paramount."

Last week's announcement by China to increase export controls on rare earths and other materials that are essential for high-technology production led American leader the US President to threaten an further 100% tariff on goods from the Asian country, increasing the prospect of an all-out trade war between the two largest economies.

The US Treasury Secretary labeled China's decision "commercial pressure" and "a global supply chain control attempt."

Questioned on considering the American proposal to participate in its battle with the Asian nation, the Chancellor said she was "deeply worried" by Chinese actions and encouraged the Chinese government "not to put up barriers and restrict access."

She said the move was "damaging for the international commerce and causes further headwinds."

"In my view there are sectors where we should address China, but there are also important opportunities to trade with Chinese markets, including financial services and other areas of the economic system. We've got to get that balance appropriate."

The chancellor also affirmed she was cooperating with G7 counterparts "on our own essential resources plan, so that we are reduced dependence."

Health Service Drug Costs and Funding

The Chancellor also acknowledged that the price the National Health Service spends on pharmaceuticals could increase as a consequence of current negotiations with the Trump administration and its drugs companies, in return for reduced taxes and investment.

Some of the biggest global pharmaceutical manufacturers have said recently that they are either delaying or abandoning investments in the UK, with some blaming the low prices they are obtaining.

Last month, the government science advisor said the price the NHS pays for medicines would need to increase to stop companies and drug research funding departing from the UK.

The Chancellor told the BBC: "It has been observed because of the cost structure, that clinical trials, new drugs have not been available in the United Kingdom in the way that they are in other continental states."

"We want to guarantee that patients getting care from the NHS are can access the finest essential drugs in the globe. And so we are reviewing all of that, and... aiming to obtain additional funding into Britain."